Omapatrilat, an Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibitor, Attenuates Early Atherosclerosis in Diabetic and in Nondiabetic Low-Density Lipoprotein Receptor–Deficient Mice

Omapatrilat inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). ACE inhibitors have been shown to inhibit atherosclerosis in apoE-deficient mice and in several other animal models but failed in low-density lipoprotein (LDL) receptor– deficient mice despite effective in...

Descripción completa

Detalles Bibliográficos
Autores principales: Levy, Zohar, Dvir, Ayana, Shaish, Aviv, Trestman, Svetlana, Cohen, Hofit, Levkovietz, Hana, Rhachmani, Rita, Ravid, Mordchai, Harats, Dror
Formato: Texto
Lenguaje:English
Publicado: 2003
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480500/
https://www.ncbi.nlm.nih.gov/pubmed/12745671
http://dx.doi.org/10.1080/15438600303728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480500/
https://www.ncbi.nlm.nih.gov/pubmed/12745671
http://dx.doi.org/10.1080/15438600303728

Ejemplares similares